99 156

Cited 7 times in

Autologous Stem Cell Transplantation for the Treatment of Neuroblastoma in Korea

Authors
 Kyung Ha Ryu  ;  Hyo Seop Ahn  ;  Tai Ju Hwang  ;  Jeong Ok Hah  ;  Hyung Soo Choi  ;  Hyun Sang Cho  ;  Bin Cho  ;  Hahng Lee  ;  Young Ho Lee  ;  Chuhl Joo Lyu  ;  Eun-Sun Yoo  ;  Hee Young Shin  ;  Ki Woong Sung  ;  Jong Jin Seo  ;  Hyung Nam Moon  ;  Thad Ghim  ;  Hack Ki Kim  ;  Moon Kyu Kim  ;  Hoon Kook  ;  Hong Hoe Koo 
Citation
 JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.18(2) : 242-247, 2003 
Journal Title
 JOURNAL OF KOREAN MEDICAL SCIENCE 
ISSN
 1011-8934 
Issue Date
2003
MeSH
Adolescent ; Child ; Child, Preschool ; Combined Modality Therapy ; Female ; Humans ; Korea ; Male ; Myeloablative Agonists/therapeutic use ; Neuroblastoma/mortality ; Neuroblastoma/pathology ; Neuroblastoma/therapy* ; Retrospective Studies ; Stem Cell Transplantation* ; Survival Rate ; Transplantation Conditioning ; Transplantation, Autologous ; Treatment Outcome
Keywords
Neuroblastoma ; stem cell transplantation ; Korea
Abstract
Autologous stem cell transplantation (ASCT) for the treatment of high-risk neuroblastoma (NBL) is an accepted method for restoring bone marrow depression after high dose chemotherapy. We retrospectively analyzed eighty eight cases of NBL that underwent ASCT following marrow ablative therapy at 12 transplant centers of the Korean Society of Pediatric Hematology-Oncology between January 1996 and September 2000. Seventy nine children were of stage IV NBL and 9 were of stage III with N-myc amplification. Various cytoreductive regimens were used. However, the main regimen was 'CEM' consisting of carboplatin, etoposide and melphalan, and this was used in 66 patients. Total body irradiation was also added in 36 patients for myeloablation. To reduce tumor cell contamination, stem cell infusions after CD34+ cell selection were performed in 16 patients. Post-transplantation therapies included the second transplantation in 18 patients, interleukin2 therapy in 45, 13-cis retinoic acid in 40, 131-meta-iodobenzylguanidine in 4, conventional chemotherapy in 11, and local radiotherapy in 8. Twenty two patients died, sixty six patients are surviving 1 to 46 months after ASCT (median followup duration, 14.5 months). Although the follow-up period was short and the number of patients small, we believe that ASCT might improve the survival rate in high-risk NBL.
Files in This Item:
T200306529.pdf Download
DOI
10.3346/jkms.2003.18.2.242
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers
Yonsei Authors
Lyu, Chuhl Joo(유철주) ORCID logo https://orcid.org/0000-0001-7124-7818
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/114401
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse